

Morten Ladekarl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2481933/publications.pdf>

Version: 2024-02-01

68
papers

1,644
citations

304602

22
h-index

315616

38
g-index

73
all docs

73
docs citations

73
times ranked

2636
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. <i>Acta Oncologica</i> , 2022, 61, 409-416.	0.8	11
2	Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI. <i>Journal of Clinical Oncology</i> , 2022, 40, 185-185.	0.8	0
3	Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. <i>Acta Oncologica</i> , 2022, 61, 277-285.	0.8	6
4	Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine–non-neuroendocrine neoplasms. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12967.	1.2	23
5	Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age. <i>Pancreas</i> , 2021, 50, 685-695.	0.5	4
6	Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2662.	1.0	13
7	Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy. <i>Cancers</i> , 2021, 13, 4846.	1.7	19
8	Prognostic significance of T-cell–inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer. <i>Cancer Medicine</i> , 2021, 10, 8365-8376.	1.3	6
9	Pilot Study Experiences With Hyperpolarized [¹³ C]pyruvate MRI in Pancreatic Cancer Patients. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 961-963.	1.9	45
10	Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis. <i>Cancer Epidemiology</i> , 2020, 64, 101647.	0.8	21
11	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	1.9	15
12	Management Recommendations for Merkel Cell Carcinoma—A Danish Perspective. <i>Cancers</i> , 2020, 12, 554.	1.7	15
13	Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. <i>European Journal of Cancer</i> , 2020, 129, 50-59.	1.3	17
14	Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma. <i>Cancers</i> , 2020, 12, 888.	1.7	8
15	PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. <i>PLoS ONE</i> , 2020, 15, e0243900.	1.1	11
16	Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers. <i>Future Science OA</i> , 2020, 6, FSO616.	0.9	10
17	The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. <i>Acta Oncologica</i> , 2019, 58, 864-871.	0.8	19
18	Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e32-e37.	0.9	18

#	ARTICLE	IF	CITATIONS
19	T-cell "inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC).. Journal of Clinical Oncology, 2019, 37, 26-26.	0.8	3
20	Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology, 2018, 35, 47.	1.2	13
21	Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study. Annals of Surgical Oncology, 2018, 25, 422-430.	0.7	26
22	Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study. PLoS ONE, 2018, 13, e0202486.	1.1	25
23	Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology, 2017, 43, 1682-1689.	0.5	46
24	Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLoS ONE, 2017, 12, e0187667.	1.1	24
25	Danish Pancreatic Cancer Database. Clinical Epidemiology, 2016, Volume 8, 645-648.	1.5	25
26	BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping. Acta Oncol ³ gica, 2016, 55, 377-381.	0.8	14
27	Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art. Acta Oncol ³ gica, 2016, 55, 3-14.	0.8	15
28	FOLFIRINOX for patients with borderline and never-resectable locally advanced pancreatic cancer, with the addition of chemoradiotherapy for potentially resectable patients: A phase II study.. Journal of Clinical Oncology, 2016, 34, 408-408.	0.8	0
29	Chemotherapy for patients with non-resectable pancreatic cancer with additional chemo-radiotherapy for patients with potentially resectable tumours: Final Results.. Journal of Clinical Oncology, 2016, 34, e15725-e15725.	0.8	1
30	Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients. PLoS ONE, 2015, 10, e0117627.	1.1	26
31	A Nationwide Retrospective Study of Perioperative Chemotherapy for Gastroesophageal Adenocarcinoma: Tolerability, Outcome, and Prognostic Factors. Annals of Surgical Oncology, 2015, 22, 1540-1547.	0.7	14
32	Postoperative but not preoperative treatment with sorafenib inhibits liver regeneration in rats. Journal of Surgical Research, 2014, 191, 331-338.	0.8	1
33	Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol ³ gica, 2014, 53, 1284-1297.	0.8	99
34	Strong Prognostic Value of Tumor-infiltrating Neutrophils and Lymphocytes Assessed by Automated Digital Image Analysis in Early Stage Cervical Cancer: A Comparator Study with Observer-assisted Stereological Assessments. The Journal of Oncopathology, 2014, 2, 1-9.	0.1	3
35	A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 337-337.	0.8	4
36	Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer. Danish Medical Journal, 2014, 61, A4819.	0.5	6

#	ARTICLE	IF	CITATIONS
37	Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. <i>Journal of Translational Medicine</i> , 2013, 11, 189.	1.8	25
38	Tumor-associated neutrophils and macrophages in non-small cell lung cancer: No immediate impact on patient outcome. <i>Lung Cancer</i> , 2013, 81, 130-137.	0.9	101
39	Advanced Hepatocellular Carcinoma in Adolescence Associated with Congenital Cholestasis: A Case Description. <i>Case Reports in Oncology</i> , 2013, 6, 98-103.	0.3	5
40	Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer. <i>British Journal of Cancer</i> , 2013, 108, 2116-2122.	2.9	95
41	Diffuse Abdominal Splenosis Mimicking Peritoneal Metastases in a 35-Year-Old Man with a Resectable Carcinoma of the Ampulla of Vater. <i>Case Reports in Oncology</i> , 2013, 6, 467-471.	0.3	6
42	Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability. <i>Scientific World Journal</i> , The, 2013, 2013, 1-6.	0.8	23
43	Sorafenib inhibits liver regeneration in rats. <i>Hpb</i> , 2013, 15, 944-950.	0.1	7
44	Tumor-associated CD66b+ neutrophil and CD8+ lymphocyte densities as independent prognostic factors for recurrence in localized cervical cancer: Automated digital image analysis and observer-assisted stereological assessments.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5532-5532.	0.8	0
45	Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. <i>Acta OncolÃ³gica</i> , 2012, 51, 234-242.	0.8	12
46	Blood and tumor inflammation markers in non-small cell lung cancer (NSCLC): Blood leukocytosis as an independent risk factor in early stage.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21110-e21110.	0.8	0
47	Malignant pheochromocytoma and paraganglioma: Three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs. <i>Acta OncolÃ³gica</i> , 2011, 50, 1255-1259.	0.8	2
48	Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. <i>Cancer Biology and Therapy</i> , 2011, 11, 732-739.	1.5	6
49	A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5Åyears. <i>Gynecologic Oncology</i> , 2008, 108, 106-111.	0.6	87
50	Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. <i>British Journal of Cancer</i> , 2007, 97, 1135-1138.	2.9	68
51	Stereologic estimation of the total numbers, the composition and the anatomic distribution of lymphocytes in cone biopsies from patients with stage I squamous cell carcinoma of the cervix uteri. <i>Apmis</i> , 2007, 115, 1321-1330.	0.9	12
52	Detection of circulating tumor lysateâ€™reactive CD4+ T cells in melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 560-566.	2.0	6
53	Choice of methodology for quantifying cancer structures in tissue sections. A comparison of 2- and 3-dimensional estimators of mitotic activity, cellularity and nuclear size in breast cancer. , 2004, 26, 97-104.		0
54	Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. <i>Radiotherapy and Oncology</i> , 2003, 67, 35-44.	0.3	140

#	ARTICLE	IF	CITATIONS
55	Objective malignancy grading: A review emphasizing unbiased stereology applied to breast tumors. <i>Apmis</i> , 1998, 106, 5-34.	0.9	2
56	Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. <i>Histopathology</i> , 1998, 32, 536-546.	1.6	45
57	The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 42, 895-898.	0.4	92
58	Significance of variations in section mounting technique for nuclear stereology and morphology in urinary bladder neoplasms. <i>Apmis</i> , 1995, 103, 892-896.	0.9	1
59	Quantitative histopathology in ductal carcinoma of the breast. Prognostic value of mean nuclear size and mitotic counts. <i>Cancer</i> , 1995, 75, 2114-2122.	2.0	27
60	Objective malignancy grading of squamous cell carcinoma of the lung. Stereologic estimates of mean nuclear size are of prognostic value, independent of clinical stage of disease. <i>Cancer</i> , 1995, 76, 797-802.	2.0	21
61	Quantitative histopathology in lymph node-negative breast cancer. Prognostic significance of mitotic counts. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1995, 427, 265-70.	1.4	6
62	The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. <i>Journal of Pathology</i> , 1995, 176, 343-352.	2.1	102
63	Immunohistochemical quantitation of oestrogen receptors and proliferative activity in oestrogen receptor positive breast cancer. <i>Journal of Clinical Pathology</i> , 1995, 48, 429-432.	1.0	18
64	The influence of tissue processing on quantitative histopathology in breast cancer. <i>Journal of Microscopy</i> , 1994, 174, 93-100.	0.8	41
65	Reproducibility of mean nuclear volume and correlation with mean nuclear area in breast cancer: An investigation of various sampling schemes. <i>Human Pathology</i> , 1994, 25, 80-85.	1.1	30
66	Prognostic, quantitative histopathologic variables in lobular carcinoma of the breast. <i>Cancer</i> , 1993, 72, 2602-2611.	2.0	24
67	Prognostic value of nucleolar size and size pleomorphism in choroidal melanomas. <i>Apmis</i> , 1993, 101, 358-368.	0.9	14
68	Quantitative histopathological variables in in situ and invasive ductal and lobular carcinomas of the breast. <i>Apmis</i> , 1993, 101, 895-903.	0.9	17